JP2023514721A5 - - Google Patents
Info
- Publication number
- JP2023514721A5 JP2023514721A5 JP2022550151A JP2022550151A JP2023514721A5 JP 2023514721 A5 JP2023514721 A5 JP 2023514721A5 JP 2022550151 A JP2022550151 A JP 2022550151A JP 2022550151 A JP2022550151 A JP 2022550151A JP 2023514721 A5 JP2023514721 A5 JP 2023514721A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980658P | 2020-02-24 | 2020-02-24 | |
| US62/980,658 | 2020-02-24 | ||
| PCT/US2021/019213 WO2021173537A1 (en) | 2020-02-24 | 2021-02-23 | Formulations of anti-endothelial lipase antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514721A JP2023514721A (ja) | 2023-04-07 |
| JP2023514721A5 true JP2023514721A5 (https=) | 2024-03-06 |
Family
ID=77492003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550151A Pending JP2023514721A (ja) | 2020-02-24 | 2021-02-23 | 抗内皮リパーゼ抗体の製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230131324A1 (https=) |
| EP (1) | EP4110290A4 (https=) |
| JP (1) | JP2023514721A (https=) |
| CN (1) | CN115297838A (https=) |
| AU (1) | AU2021227871A1 (https=) |
| CA (1) | CA3211692A1 (https=) |
| TW (1) | TWI887362B (https=) |
| WO (1) | WO2021173537A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| AR060487A1 (es) * | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| JP6635655B2 (ja) * | 2011-12-08 | 2020-01-29 | アムジエン・インコーポレーテツド | ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用 |
| CN104768578A (zh) * | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| WO2015095568A1 (en) * | 2013-12-18 | 2015-06-25 | Kelvin Lee | Reduction of lipase activity in product formulations |
| CA2959571A1 (en) * | 2014-09-03 | 2016-03-10 | Medimmune Limited | Stable anti-il-4r-alpha antibody formulation |
| TWI688575B (zh) * | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
-
2021
- 2021-02-23 JP JP2022550151A patent/JP2023514721A/ja active Pending
- 2021-02-23 CA CA3211692A patent/CA3211692A1/en active Pending
- 2021-02-23 EP EP21760163.2A patent/EP4110290A4/en active Pending
- 2021-02-23 WO PCT/US2021/019213 patent/WO2021173537A1/en not_active Ceased
- 2021-02-23 CN CN202180016623.6A patent/CN115297838A/zh active Pending
- 2021-02-23 US US17/801,670 patent/US20230131324A1/en active Pending
- 2021-02-23 AU AU2021227871A patent/AU2021227871A1/en active Pending
- 2021-02-24 TW TW110106493A patent/TWI887362B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| JP7046088B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| JP4890537B2 (ja) | 安定化抗ｂ型肝炎ウイルス（ｈｂｖ）抗体製剤 | |
| JP2021512881A5 (https=) | ||
| JP2022036932A5 (https=) | ||
| JP2018188437A5 (https=) | ||
| JP2021504372A5 (https=) | ||
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| JP2022532927A5 (https=) | ||
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| JP2019512012A5 (https=) | ||
| JP2023513833A5 (https=) | ||
| JP2024138284A5 (https=) | ||
| JP2024534947A5 (https=) | ||
| JP2024515968A5 (https=) | ||
| JP2019532970A5 (https=) | ||
| JP2023553538A5 (https=) | ||
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2020531523A5 (https=) | ||
| JP2023514721A5 (https=) | ||
| JP7804590B2 (ja) | 抗ｉｌ－３３抗体の処方物 | |
| CN113813377A (zh) | 抗α4β7抗体制剂及其应用 | |
| FR2466454A1 (fr) | Peptides ayant des proprietes immunostimulantes et compositions pharmaceutiques les contenant | |
| JP2023532203A5 (https=) | ||
| JP2024539502A5 (https=) |